Results 21 to 30 of about 10,024 (235)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection

Journal of Family Medicine and Primary Care, 2022
Molnupiravir is a novel antiviral agent for coronavirus disease 2019 (COVID-19) treatment. Warfarin is an oral anticoagulation agent with difficult management due to drug interactions.
Hikari Mizutani, Tetsuro Koide, Takashi Omura, Kumiko Ito   +3 more
doaj   +1 more source

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals medicus, 2022
Background The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a simple oral ...
Wen Wen, Chen Chen, Jiake Tang, Chunyi Wang, Mengyun Zhou, Yongran Cheng, Xiaoping Zhou, Qi Wu, Xing-wei Zhang, Zhanhui Feng, Mingwei Wang, Qin Mao   +11 more
semanticscholar   +1 more source

Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

Clinical Infectious Diseases, 2022
At a crucial time with rapid spread of Omicron SARS-CoV-2 virus variant globally, the United States Food and Drug Administration has issued an emergency use authorization for two oral antivirals molnupiravir (>18 years) and nirmatrelvir-ritonavir ...
L. Saravolatz, Shawn Depcinski, Mamta Sharma   +2 more
semanticscholar   +1 more source

MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY [PDF]

, 2023
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates.
Adžić-Vukičević, Tatjana, Arellano, Elena, Bavastro, Martina, Besson, Caroline, Biernat, Monika M, Blennow, Ola, Buquicchio, Caterina, Calbacho, María, Cattaneo, Chiara, Cordoba, Raul, Cornely, Oliver A, Criscuolo, Mariana, Dargenio, Michelina, Del Principe, Maria Ilaria, Delia, Mario, Dávila-Valls, Julio, Erben, Nurettin, Espigado, Ildefonso, Falces-Romero, Iker, Farina, Francesca, Fouquet, Guillemette, Fracchiolla, Nicola S, García-Bordallo, Daniel, Gavriilaki, Eleni, Glenthøj, Andreas, Gräfe, Stefanie, Hernández-Rivas, José-Ángel, Hersby, Ditte Stampe, Itri, Federico, Koehler, Philipp, Kohn, Milena, Labrador, Jorge, Lavilla-Rubira, Esperanza, Limongelli, Alessandro, López-García, Alberto, Marchesi, Francesco, Marchetti, Monia, Martín-Pérez, Sonia, Meers, Stef, MelisÇOLAK, Gökçe, Merelli, Maria, Mitrovic, Mirjana, Mišković, Bojana, Mladenović, Miloš, Nordlander, Anna, Pagano, Livio, Pantic, Nikola, Petzer, Verena, Praet, Jens VAN, Prezioso, Lucia, Rahimli, Laman, Romano, Alessandra, Salmanton-García, Jon, Schönlein, Martin, Sili, Uluhan, Tascini, Carlo, Tragiannidis, Athanasios, Vena, Antonio, Weinbergerová, Barbora, Wolf, Dominik, Čolović, Natasa   +60 more
core   +3 more sources

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molecules, 2021
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd. Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Saleh I. Alaqel, Mohammed Kanan Alshammari, Mohammed M. Alshehri, Ahmed Subeh Alshrari, Alreshidi Mateq Ali, Ahmed Muteb Al-shammeri, Bushra Dhuhayyan Alhazmi, Aishah Ali Harshan, Md. Tauquir Alam, Abida   +13 more
doaj   +1 more source

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro

Viruses, 2023
Porcine epidemic diarrhea virus (PEDV) is a swine coronavirus that is highly infectious and prone to variation. Vaccines derived from traditional PEDV strains provide less protection against PEDV-variant strains. Furthermore; there is a complex diversity
Zi-Xin Huang, Shu-Ting Zhou, Zhi-Biao Yang, Zhe Wang   +3 more
doaj   +1 more source

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Frontiers in Pharmacology, 2022
Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective ...
Rongrong Zou, Ling Peng, Dan Shu, Lei Zhao, Jianfeng Lan, Guoyu Tan, Jinghan Peng, Xiangyi Yang, Miaona Liu, Chenhui Zhang, Jing Yuan, Huxiang Wang, Song Li, Hongzhou Lu, Wu Zhong, Yingxia Liu   +15 more
doaj   +1 more source

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Nature Structural & Molecular Biology, 2021
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in
F. Kabinger, C. Stiller, J. Schmitzová, C. Dienemann, G. Kokic, H. S. Hillen, C. Höbartner, P. Cramer   +7 more
semanticscholar   +1 more source

Molnupiravir: a new hope in the treatment of COVID-19 [PDF]

, 2022
Coronavirus disease-19 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing pandemic since its first emergence in Wuhan, China in December 2019.1 Most of the people with COVID-19 ...
Paudel, Rama
core   +2 more sources

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

bioRxiv, 2021
We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524, molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor nirmatrelvir against the ancestral SARS-CoV2 strain and the five variants of ...
L. Vangeel, Winston Chiu, S. de Jonghe, P. Maes, Bram Slechten, J. Raymenants, E. André, P. Leyssen, J. Neyts, D. Jochmans   +9 more
semanticscholar   +1 more source